User: Guest  Login
Document type:
Journal Article; Randomized Controlled Trial; Article
Author(s):
Pfisterer, J; du Bois, A; Bentz, EK; Kommoss, F; Harter, P; Huober, J; Schmalfeldt, B; Burchardi, N; Arnold, N; Hilpert, F
Title:
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Abstract:
OBJECTIVES: Results on the prognostic value of human epidermal growth factor receptor 2 (HER-2)/neu in ovarian cancer are inconsistent. This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial. METHODS: Her-2/neu expression was assessed by immunohistochemistry in 359 patients (46%) treated within the AGO-OVAR 3 trial (n = 7...     »
Journal title abbreviation:
Int J Gynecol Cancer
Year:
2009
Journal volume:
19
Journal issue:
1
Pages contribution:
109-15
Language:
eng
Fulltext / DOI:
doi:10.1111/IGC.0b013e3181991a7c
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/19258951
Print-ISSN:
1048-891X
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX